Premium
Single nedaplatin treatment as salvage chemotherapy for platinum/taxane‐resistant/refractory epithelial ovarian, tubal and peritoneal cancers
Author(s) -
Goto Tomoko,
Takano Masashi,
Ohishi Rie,
Iwasa Norihiro,
Shimizu Motohiro,
Hasegawa Kosei,
Nagao Shoji,
Fujiwara Keiichi
Publication year - 2010
Publication title -
journal of obstetrics and gynaecology research
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.597
H-Index - 50
eISSN - 1447-0756
pISSN - 1341-8076
DOI - 10.1111/j.1447-0756.2010.01217.x
Subject(s) - medicine , nedaplatin , taxane , regimen , chemotherapy , gastroenterology , progressive disease , salvage therapy , refractory (planetary science) , surgery , ovarian cancer , oncology , cancer , breast cancer , cisplatin , physics , astrobiology
Aim: To evaluate toxicity, response and progression‐free survival of single nedaplatin chemotherapy in women with platinum/taxane‐resistant/refractory epithelial ovarian, tubal and peritoneal cancer. Methods: Seventeen patients with platinum/taxane‐resistant/refractory epithelial ovarian, fallopian tube or primary peritoneal cancer who were treated with a single nedaplatin regimen at 90 mg/m 2 administration on day 1 of a 28‐day cycle in our institution between 2005 and 2007 were retrospectively investigated. Results: Ten of 17 patients (59%) had measurable disease. Seven patients were evaluated according to cancer antigen (CA) 125 levels. The overall response was 24% (complete response, 2 patients; partial response, 2 patients). Two of these 4 patients had measurable disease. Stable disease and progressive disease was noted in 6 (35%) and 7 (41%) patients. Median progression‐free survival was 8 months (range 3–11) in patients who responded to therapy and 4 months (range 2–6) in patients with stable disease. Mean platinum‐free interval due to treatment without using platinum analogues after developing platinum‐resistant/refractory disease was 11 months (range 8–12) in patients who responded to nedaplatin regimen and 3 months (range 1–11) in patients who did not ( P < 0.01), whereas mean treatment‐free interval was 3 months (range 1–5) in responders and 1 month (range 1–3) in non‐responders, which did not show a significant difference. Grade 4 hematological toxicity was observed in 2 of 17 patients (12%). No grade 3 or 4 non‐hematological toxicity occurred. All toxicities were managed on an outpatient basis. Conclusions: Single nedaplatin treatment for platinum/taxane‐resistant/refractory ovarian, tubal and peritoneal cancer patients is the candidate of salvage chemotherapy with comparable effectiveness and less toxicity to other approved regimens.